Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Titel:
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Auteur:
Eckstein, Markus Erben, Philipp Kriegmair, Maximilian C. Worst, Thomas S. Weiß, Cleo-Aron Wirtz, Ralph M. Wach, Sven Stoehr, Robert Sikic, Danijel Geppert, Carol I. Weyerer, Veronika Bertz, Simone Breyer, Johannes Otto, Wolfgang Keck, Bastian Burger, Maximilian Taubert, Helge Weichert, Wilko Wullich, Bernd Bolenz, Christian Hartmann, Arndt Erlmeier, Franziska